CanSinoBIO develops immunisation methods against deadly diseases
- With five approved vaccines against Covid-19, Ebola and meningococcal disease, CanSinoBIO also provides novel delivery of immunisation methods
Country Business Reports interviews and articles by Discovery Reports
An ounce of prevention is worth a pound of cure, especially in the biopharmaceutical industry. Using innovative technology platforms, CanSinoBIO is poised to continue preventing a plethora of illnesses.
The mainland China-based company has developed five approved vaccines that prevent Covid-19, Ebola and meningococcal disease. It is also now working towards providing more potential first-in-class and best-in-class vaccines that prevent meningitis, pneumonia, tuberculosis, Covid-19, Ebola virus disease, shingles, diphtheria, tetanus and pertussis (DTP), and many more.
“We have a strong founding team and a leadership with a wealth of experience internationally and domestically,” said Yu Xuefeng, co-founder, chairman and CEO. “We all share the same vision: to develop as a global vaccine leader.”
CanSinoBIO develops its pipeline of vaccines through five technology platforms. Its synthetic vaccine technology supports the advancement of its bivalent and quadrivalent meningococcal vaccines, pneumococcal conjugate vaccines and the component DTP vaccine portfolio.
Through its viral vector-based technology, CanSinoBIO produced a vaccine against Ebola that demonstrated high safety and immunogenicity in clinical trials in Africa during outbreaks in 2014 and 2015. The company is also set to manufacture a viral vector booster against tuberculosis.
Because recombinant protein technology does not use violent viral strains to produce vaccines, CanSinoBIO upholds the safety of the environment during vial processing. Through this method, the company has designed pneumococcal protein antigens, along with novel recombinant strains for use in its latest pertussis vaccine.
CanSinoBIO recently developed its messenger ribonucleic acid (mRNA) technology for applications beyond fighting Covid-19. Through its mRNA vaccines, the company eyes providing broad-spectrum protection against meningococcal infections.
CanSinoBIO’s formulation technologies allow for novel delivery of immunisation methods, such as inhalation instead of injection, for its Covid-19 vaccine Convidecia – potentially ending transmission. This technology has also granted its Ebola vaccine stability in hotter climates.
“We seek partners who have a good local outreach to regulatory agencies, local markets, government and the medical community, and share similar values, understanding and vision,” Yu said.